Encouragingly, sodium glucose cotransporter 2 (SGLT2) inhibitors are a new class of glucose‐lowering agents recently approved in type 2 diabetes mellitus (T2DM).8 This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.